checkAd

    Artes Medical - Börsengang mit Top Aussichten - 500 Beiträge pro Seite

    eröffnet am 15.12.06 12:22:49 von
    neuester Beitrag 30.11.07 14:59:56 von
    Beiträge: 48
    ID: 1.100.655
    Aufrufe heute: 0
    Gesamt: 4.357
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 15.12.06 12:22:49
      Beitrag Nr. 1 ()
      Hier die website: www.artesmedical.com

      Weitere Infos folgen in Kürze;)
      Avatar
      schrieb am 15.12.06 12:35:30
      Beitrag Nr. 2 ()
      Das Kürzel lautet ARTE und die WKN ist A0LFLT.

      Momentan stellt Artes Medical lediglich ein einziges Produkt her, nämlich Artefill. Dies ist der erste permanente Faltenfüller mit FDA-Zulassung in den USA. Andere Faltenfüller wie Botox oder Collagen haben nur eine begrenzte Wirkung von ca. 3 - 6 Monaten (Angaben ohne Gewähr). Auf die USA wird sich konzentriert. Die Produkteinführung soll Beginn 2007 stattfinden. Folglich wurden noch keinerlei Umsätze generiert und hohe Verluste angehäuft.
      Wird das Produkt gut vom Markt angenommen - und davon gehe ich aus - ist die aktuelle Marketcap als sehr gering einzustufen.
      Neben Falten ergeben sich eine Vielzahl weitere Anwendungsbereiche, an denen momentan geforscht wird. Siehe hierzu den Punkt "Productpipeline" auf der website.

      Die Aktie ist wohl nichts für schwache Nerven. Vom Rohrkrepierer bis zum shootingstar ist alles möglich.;)
      Avatar
      schrieb am 15.12.06 13:28:20
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 26.201.953 von c-laus am 15.12.06 12:35:30Wann ist die "Erstnotierung"?

      Woher kennst Du Artes Medical und was sind Deine
      Umsatzerwartungen für das Jahr 2007?
      Avatar
      schrieb am 15.12.06 14:47:59
      Beitrag Nr. 4 ()
      Antwort auf Beitrag Nr.: 26.203.071 von sonne11 am 15.12.06 13:28:20Die Erstnotierung wird heute oder Anfang nächster Woche erfolgen, soweit ich weiss.
      Ich kenne das Unternehmen schon lange. Ich bin schon vor Jahren eingestiegen. Seitdem hat sich das Unternehmen rasant weiterentwickelt. Nach Börsengang verkaufen werde ich nicht, da ich ein Lock-up habe und vom Unternehmen überzeugt bin.

      Die Aktie eignet sich nur für risikobewusste Investore, soviel ist klar.

      Umsätze in 2007? Gehen wir mal von der bescheidenen Annahme aus, dass in jedem Bundesstaat in den USA nur 10 Patienten pro Wochentag (a´3 Spritzen) behandelt werden. Bei von mir geschätzten Preis pro Spritze von 700 $ sind dies 52 x 10 x 3 x 700 = ca. 1,1 Mio $ Tagesumsätze.
      Multipliziert mit ca. 250 Arbeitstagen pro Jahr ergibt 275 Mio $ Jahresumsatz (mehr als die Marketcap!). Das Zahlenspiel ist von mir frei erfunden. Aber ich denke, dass man hiervon mindestens ausgehen kann. Und Artefill hat eine recht hohe Gewinnmarge:lick:
      Avatar
      schrieb am 15.12.06 15:34:15
      Beitrag Nr. 5 ()
      Antwort auf Beitrag Nr.: 26.204.849 von c-laus am 15.12.06 14:47:59ok, Du bist also auch schon länger dabei.
      Bist Du direkt über die Familie Lemperle dazugekommen?
      Ich bin seit dem Jahre 2000 dabei. Was mich verunsichert ist
      der Management wechsel, so kurz vor Börsengang.
      Weisst Du mehr darüber warum und wieso?

      However hat auch die positiven Seiten. Jetzt können andere,
      Leute Marketing und Sales sowie den Produktelaunch vorantreiben.

      Meine Umsatzschätzung für 2007 ist Mio USD 50, für das 2008
      gehe ich von Mio USD 100 aus. Wenn dem so ist, ist die Aktie
      viel zu billig, Faktor vier bis sechs ist möglich (in zwei Jahren).
      Einziges Problem momentan, keine Umsätze und ??? ob das Produkt auch hält, was man davon sagt/erfährt....
      Wie gesagt, dies sind meine Schätzung und sicher das best case scenario.

      We will see

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 15.12.06 15:41:03
      Beitrag Nr. 6 ()
      Ja, ich kenne die Familie Lemperle. Hast Du ja ins Schwarze getroffen.
      Für den Managemnetwechsel gibt es Gründe.
      Angeblich hat Lemperle sen. das Produkt bei einer Patientin angewendet, als es noch keine FDA-Zulassung hatte. Vielleicht war es so eine Art Bauernopfer?!
      Schicke Dir ne boardmail mit meiner Nummer!:)
      Avatar
      schrieb am 15.12.06 16:03:04
      Beitrag Nr. 7 ()
      Antwort auf Beitrag Nr.: 26.206.255 von c-laus am 15.12.06 15:41:03...habe die Boardmail mit der Nummer erhalten.

      Jetzt musst Du mich aber noch aufklären, was bedeutet diese
      Nummer?
      Avatar
      schrieb am 15.12.06 16:07:33
      Beitrag Nr. 8 ()
      Antwort auf Beitrag Nr.: 26.206.862 von sonne11 am 15.12.06 16:03:04Das ist meine Handynummer;)
      Avatar
      schrieb am 15.12.06 16:30:22
      Beitrag Nr. 9 ()
      Antwort auf Beitrag Nr.: 26.206.993 von c-laus am 15.12.06 16:07:33..Vorwahl, respektive von welchem Land?
      Avatar
      schrieb am 15.12.06 17:01:44
      Beitrag Nr. 10 ()
      Antwort auf Beitrag Nr.: 26.204.849 von c-laus am 15.12.06 14:47:59Artes Medical IPO delayed

      PrintDisable live quotesRSSDigg itDel.icio.usBy Steve Gelsi
      Last Update: 9:26 AM ET Dec 15, 2006



      NEW YORK (MarketWatch) -- Artes Medical Inc. is delaying it IPO for Friday and will try to price the deal again on Monday, according to the syndicate desk at Cowen & Co. The company hopes to raise about $60 million in the IPO. Six other IPOs managed to debut on Friday. Artes Medical makes a botox competitor to reduce wrinkles.
      Avatar
      schrieb am 18.12.06 22:26:26
      Beitrag Nr. 11 ()
      Antwort auf Beitrag Nr.: 26.208.375 von sonne11 am 15.12.06 17:01:44Soweit ich weiss, soll es morgen soweit sein...
      Avatar
      schrieb am 19.12.06 20:24:01
      Beitrag Nr. 12 ()
      Der Preis wurde soeben von 12-14 auf 6-8 $ herabgesetzt. Das ist sehr wenig. So wenig, dass ich überlege, über die Börse nachzukaufen. Hätte ich nicht gedacht.:(
      Avatar
      schrieb am 21.12.06 12:39:38
      Beitrag Nr. 13 ()
      Gestern wurde der Börsengang vollzogen. Ich hatte versucht, bei 6,50 $ einige Stücke einzusammeln. Aber ich kam leider zu spät!
      Nun ja, nachdem der Kurs von 6 auf 9,50 lief, schloss er bei 7,67 $. Ich denke, der Kurs wird erstmal zwischen 6 und 12 $ dümpeln. Sobald die ersten Umsätze im 1. Quartal kommen, wird sich zeigen, wohin die Reise geht.:cool:
      Avatar
      schrieb am 21.12.06 15:32:32
      Beitrag Nr. 14 ()
      Konkurrenz?

      8:14AM Anika Therapeutics receives FDA approval for its cosmetic tissue augmentation product (ANIK) 13.39 : Co announces that it has received FDA approval for its cosmetic tissue augmentation product. C.T.A is an injectable soft tissue filler for facial wrinkles, scar remediation and lip augmentation. The co had previously announced on Nov 28, 2006 that it had received an approvable letter for its product.
      Avatar
      schrieb am 21.12.06 16:12:55
      Beitrag Nr. 15 ()
      Antwort auf Beitrag Nr.: 26.371.988 von Schapekop am 21.12.06 15:32:32Hier geht es aber nicht um permanent filler, oder?:confused:
      Avatar
      schrieb am 21.12.06 16:28:42
      Beitrag Nr. 16 ()
      Antwort auf Beitrag Nr.: 26.373.121 von c-laus am 21.12.06 16:12:55Keine Ahnung-

      These products are based on hyaluronic acid, a naturally occurring, biocompatible polymer found throughout the body

      kann wohl sein.:rolleyes:
      Avatar
      schrieb am 26.12.06 19:02:33
      Beitrag Nr. 17 ()
      Antwort auf Beitrag Nr.: 26.373.603 von Schapekop am 21.12.06 16:28:42Insider haben heute kräftig gekauft:eek:
      Avatar
      schrieb am 26.12.06 19:39:12
      Beitrag Nr. 18 ()
      Antwort auf Beitrag Nr.: 26.477.878 von c-laus am 26.12.06 19:02:33Z.B. Reinhard:
      1.Title of Security
      (Instr. 3) 2. Transaction Date (Month / Day / Year) 2A. Deemed Execution Date, if any (Month / Day / Year) 3. Transaction Code
      (Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
      (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
      (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I)
      (Instr. 4) 7. Nature of Indirect Beneficial Ownership
      (Instr. 4)
      Code V Amount (A) or (D) Price
      Common Stock 12/26/2006 C 20,139 A 66,946 D
      Avatar
      schrieb am 27.12.06 10:42:45
      Beitrag Nr. 19 ()
      Antwort auf Beitrag Nr.: 26.478.474 von c-laus am 26.12.06 19:39:12Schlusskurs 9,05 $!

      Die Richtung stimmt so langsam;)
      Avatar
      schrieb am 27.04.07 22:38:53
      Beitrag Nr. 20 ()
      Am 03. Mai 2007 kommen die Zahlen über die Produktverkäufe!
      Sollten diese gut ausfallen, würde das einem Startschuß für die Aktie gleichkommen. Denn dann haben die Analysten endlich Anhaltspunkte, um Umsätze und Gewinne hochzurechnen. Könnte mir vorstellen, dass dann eine marketcap von 400.000.000 $ gesehen wird.

      Es wird endlich sehr, sehr spannend!:)
      Avatar
      schrieb am 27.04.07 22:43:05
      Beitrag Nr. 21 ()
      Antwort auf Beitrag Nr.: 29.037.177 von c-laus am 27.04.07 22:38:53Habe gestern nochmal kräftig nachgekauft!
      Avatar
      schrieb am 27.04.07 22:46:31
      Beitrag Nr. 22 ()
      Antwort auf Beitrag Nr.: 29.037.177 von c-laus am 27.04.07 22:38:53http://www.youtube.com/watch?v=1q3JXhpoNGk
      Avatar
      schrieb am 02.05.07 11:35:49
      Beitrag Nr. 23 ()
      Antwort auf Beitrag Nr.: 29.037.242 von c-laus am 27.04.07 22:46:31Artes Medical, Inc. has added a news release to its Investor Relations website.

      Title: Artes Medical to Announce Financial Results for the First Quarter Ended March 31, 2007
      Date: 5/1/2007 5:52:09 PM
      Avatar
      schrieb am 03.05.07 13:58:45
      Beitrag Nr. 24 ()
      Antwort auf Beitrag Nr.: 29.091.963 von c-laus am 02.05.07 11:35:49 - Initial Sales of ArteFill(R) Exceed $1.4 Million -

      SAN DIEGO--(BUSINESS WIRE)--May 3, 2007--Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today reported recent company highlights and financial results for the first quarter ended March 31, 2007.

      Recent Company Highlights

      -- Initial Shipments of ArteFill- The Company began shipping
      ArteFill, the first and only FDA-approved non-resorbable
      injectable dermal filler for the correction of wrinkles known
      as smile lines or nasolabial folds, to physicians in February
      2007.

      -- Presentations at the Two Leading Dermatology and Plastic
      Surgery Medical Conferences - 5 year U.S. pivotal study
      results were presented by Dr. Steven R. Cohen, M.D., F.A.C.S.,
      Clinical Professor, Division of Plastic Surgery, University of
      California, San Diego, School of Medicine and lead ArteFill
      clinical investigator, at the annual meeting of the American
      Society for Aesthetic Plastic Surgery in April 2007 in New
      York City. This data was also presented by Dr. Mark G. Rubin,
      M.D., Assistant Clinical Professor of Dermatology, University
      of California, San Diego, Division of Dermatology, at the
      meeting of the American Academy of Dermatology in February
      2007 in Washington D.C.

      -- FDA Submission for Enhanced Product Labeling - On March 21,
      2007, the Company submitted the final results of a 5-year
      efficacy and safety study of ArteFill to the FDA in order to
      enhance product labeling.

      "We began shipping ArteFill to trained physicians in early February 2007, and we are pleased with the initial market receptivity of ArteFill. Numerous physicians have reported ArteFill's ease of administration and immediate aesthetic improvement. The initial physician and patient feedback and our market and focus group research confirm that many patients who currently use temporary dermal fillers requiring repeat injections are 'credit card-fatigued' and 'injection-fatigued.' We believe these patients lead busy and active lives and want to avoid the cyclical short-term effects provided by current temporary dermal filler treatments. We believe that ArteFill's differentiated formulation provides an enduring solution for the correction of smile lines which benefits both patients and physicians who have been seeking a long-lasting dermal filler," said Diane S. Goostree, President and Chief Executive Officer.

      Financial Results

      The Company reported sales of $1.4 million for first quarter ended March 31, 2007. The first quarter 2007 results reflect the initial sales of ArteFill that commenced in February 2007.

      The Company also reported a net loss of $6.6 million for the first quarter ended March 31, 2007, a decrease of $1.4 million compared to the prior year 2006 first quarter net loss of $8.0 million.

      Total operating expenses for the first quarter ended March 31, 2007 were $6.6 million, an increase of $459,000, over the first quarter 2006 operating expenses of $6.1 million. The increase in operating expenses from first quarter 2006 to first quarter 2007 is primarily attributable to the transition of the Company from a development stage organization to a commercial operation required in order to manufacture and distribute our FDA-approved product ArteFill, including the hiring of our national sales force.

      As of March 31, 2007, the Company reported $5.5 million in inventory, an increase of $724,000 from the December 31, 2006 inventory of $4.8 million.

      Cash, cash equivalents and short-term investments were $38.3 million as of March 31, 2007.
      Avatar
      schrieb am 03.05.07 14:17:33
      Beitrag Nr. 25 ()
      Antwort auf Beitrag Nr.: 29.111.827 von c-laus am 03.05.07 13:58:451,4 Mio in 1,5 Monate.

      Kannst du diese Zahl einordnen? Market cap ist schon 150 Mio.:rolleyes: Was hast du erwartet?
      Avatar
      schrieb am 03.05.07 18:08:36
      Beitrag Nr. 26 ()
      Antwort auf Beitrag Nr.: 29.112.167 von Schapekop am 03.05.07 14:17:33Ich habe bessere Zahlen erwartet. Aber das wird hoffentlich noch kommen, wenn es bekannter wird.:confused:
      Avatar
      schrieb am 13.05.07 10:40:53
      Beitrag Nr. 27 ()
      Antwort auf Beitrag Nr.: 29.116.941 von c-laus am 03.05.07 18:08:36bin über dieses Kommentar in einem Board gestolpert-

      http://www.investorshub.com/boards/read_msg.asp?message_id=1…
      Avatar
      schrieb am 08.06.07 13:41:07
      Beitrag Nr. 28 ()
      Antwort auf Beitrag Nr.: 29.288.204 von Schapekop am 13.05.07 10:40:53 SAN DIEGO--(BUSINESS WIRE)--June 6, 2007--Artes Medical, Inc. (Nasdaq:ARTE) today announced it will present at the 28th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 12, 2007 at 3:20 p.m. Pacific Time at The Ritz-Carlton Laguna Niguel in Dana Point, California. Diane S. Goostree, President and Chief Executive Officer, Artes Medical, will provide a corporate overview of the company.

      A live audio webcast of the presentation will be accessible through Artes Medical's Investor Relations Web site at http://ir.artesmedical.com. An archived edition of the presentation will be available later that day and archived for 180 days.
      Avatar
      schrieb am 08.06.07 13:42:09
      Beitrag Nr. 29 ()
      Jawoll!:lick:
      06/07/07 Artes Medical Launches Physician Locator on Website Providing Consumer Access to Over 500 ArteFill-Trained Physicians

      SAN DIEGO--(BUSINESS WIRE)--June 7, 2007--Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced the launch of its physician locator on the ArteFill.com website, providing consumers the opportunity to easily identify an ArteFill-trained physician in their area. Artes Medical markets ArteFill®, the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds.

      The web-based physician locator has been provided in response to the thousands of consumers who have contacted the Company requesting more information about ArteFill and access to an injection-trained physician. The locator allows consumers to enter their zip code and locate trained physicians in their area.

      "We are pleased to provide this information to the many consumers who have been seeking a long-lasting, cost-effective wrinkle treatment," stated Diane S. Goostree, President and CEO. "The physician community has been very receptive to the idea of adding a differentiated product such as ArteFill to their practices. Since our February 2007 ArteFill product launch, over 500 board certified dermatologists, plastic surgeons, and cosmetic surgeons have completed our training program and we are well on the way to achieving our stated goal of training at least 600 physicians by the end of the year. This is a highly concentrated market, and our physician customer group includes the most experienced injectors in the dermal filler area. We are continuing to train additional physicians and will be adding them to our physician locator on an ongoing basis."
      Avatar
      schrieb am 11.06.07 10:14:40
      Beitrag Nr. 30 ()
      Antwort auf Beitrag Nr.: 29.703.856 von c-laus am 08.06.07 13:42:09Morgen ist in San Diego die Hauptversammlung von Artes. Und am gleichen Tage ist die Goldman Sachs Konferenz.

      Ich denke, der Kurs wird ausbrechen wollen; wird aber gehindert durch Abverkäufe aus Angst vor dem Ende der lock-up-Frist. Diese endet am 17. Juni! Danach wird es wahrscheinlich nach oben schiessen.
      Avatar
      schrieb am 12.06.07 16:11:38
      Beitrag Nr. 31 ()
      06/12/07 Artes Medical Forms New Subsidiary to Commercially Develop and License Medical Applications of Its Microsphere Technology


      SAN DIEGO--(BUSINESS WIRE)--June 12, 2007--Artes Medical, Inc. (Nasdaq:ARTE) today announced the formation of a new wholly-owned subsidiary named Spheris Medical, Inc. to develop and commercialize new and innovative medical applications of its proprietary microsphere tissue bulking technology. Artes Medical's proprietary technology is currently incorporated in ArteFill(R), the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. Artes Medical will license the non-aesthetic applications of its medical technology to Spheris Medical, which going forward will focus on the development of new product applications, enter into licensing arrangements and selected strategic partnerships.

      Spheris Medical plans to apply Artes Medical's patented microsphere technology to develop soft tissue augmentation products which provide long-lasting tissue reshaping for a variety of therapeutic uses. In pre-clinical studies, materials produced with the Artes Medical technology have been used to provide bulking of the esophageal sphincter and the urinary sphincter to assess the possible use of the technology for the treatment of GERD (Gastro Esophageal Reflux Disease) and SUI (Stress Urinary Incontinence). Other non-company pre-clinical studies have also been conducted to evaluate the technology for spinal disk bulking and repair. Additional potential uses include bulking of the soft palate and respiratory tissue to treat snoring for patients with sleep apnea, adding cushioning to the bottom of the foot to treat painful foot syndrome, and treatment of fecal incontinence.
      Avatar
      schrieb am 12.06.07 17:49:05
      Beitrag Nr. 32 ()
      aha - Technologie in einen Tochterunternehmen unterbringen :rolleyes:

      Ist normalerweise Vorbote für ein Sell-off- entweder vom Mutter oder Tochter.;)
      Avatar
      schrieb am 12.06.07 22:22:55
      Beitrag Nr. 33 ()
      Antwort auf Beitrag Nr.: 29.847.453 von Schapekop am 12.06.07 17:49:05Muss nicht unbedingt sein. Und wenn, was ist daran schlimm, wenn der Preis stimmt? Außerdem behält Artes ohnehin die Technologie für Artefill!

      Nacher beginnt die Konferenz bei Goldman Sachs. Mal sehen, was das gibt?:rolleyes:
      Avatar
      schrieb am 02.07.07 20:44:06
      Beitrag Nr. 34 ()
      Antwort auf Beitrag Nr.: 26.201.768 von c-laus am 15.12.06 12:22:49Morgen kommen die Verkaufszahlen für Q2:kiss:
      Avatar
      schrieb am 15.07.07 19:16:46
      Beitrag Nr. 35 ()
      Antwort auf Beitrag Nr.: 30.455.976 von c-laus am 02.07.07 20:44:06auf der homepage sind keine Zahlen vermerkt.
      hast du nähere info´s ???

      wenn ja, kannst du sie bitte reinstellen ?

      gruß elsolivars
      Avatar
      schrieb am 17.07.07 15:27:39
      Beitrag Nr. 36 ()
      Antwort auf Beitrag Nr.: 30.701.695 von elsolivars am 15.07.07 19:16:46Ja, es war eine Fehlinformation.
      Die Verkaufszahlen werden mit dem Quartalsergenis am 6. August veröffentlicht. Diese Zahlen werden sehr wichtig sein!

      Sorry!
      Avatar
      schrieb am 17.07.07 15:29:18
      Beitrag Nr. 37 ()
      Antwort auf Beitrag Nr.: 30.727.620 von c-laus am 17.07.07 15:27:3907/17/07 Artes Medical Names Greg J. Kricorian, M.D. as Its Chief Medical Officer


      SAN DIEGO--(BUSINESS WIRE)--July 17, 2007--Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced the appointment of Greg J. Kricorian, M.D. to the newly created role of Chief Medical Officer.

      Dr. Kricorian will report to Artes Medical's President and Chief Executive Officer, Diane S. Goostree, and will have responsibility for the clinical development and medical affairs departments. He will also chair the Company's Medical Advisory Board (MAB), and focus on enhancing the Company's involvement in the medical community. He will play a key role in Artes Medical's newly formed wholly-owned subsidiary, Spheris Medical, Inc., which will focus on developing and commercializing new and innovative medical applications based on the Company's proprietary microsphere tissue bulking technology.

      "Greg has significant experience in the commercial development of dermatology products as well as in the design, execution and management of clinical studies of innovative aesthetic products," said Ms. Goostree. "Additionally, his strong relationships with the medical community will strengthen our management team as we move forward with our marketing launch campaign for ArteFill(R)."

      Dr. Kricorian has over 10 years experience in the clinical and business development of cosmetic and aesthetic dermatology products. Prior to joining Artes Medical, he served as Senior Director, Medical Affairs for Valeant Pharmaceuticals International, a leading global specialty pharmaceutical company. Previously, Dr. Kricorian held positions of increasing responsibility at ICN Pharmaceuticals (now Valeant) and Dermatology Associates of San Diego, where he was a practicing physician focusing on aesthetic procedures, including dermal fillers and conducted and published research studies in aesthetic dermatology. Dr. Kricorian received his Bachelor of Science in Biology from University of California, Los Angeles; his M.D. at Stanford University Medical School; and his Masters of Business Administration from the University of California, Los Angeles. Additionally, Dr. Kricorian received his Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society.
      Avatar
      schrieb am 30.07.07 08:28:10
      Beitrag Nr. 38 ()
      Avatar
      schrieb am 30.07.07 08:29:20
      Beitrag Nr. 39 ()
      Avatar
      schrieb am 30.07.07 08:30:27
      Beitrag Nr. 40 ()
      Antwort auf Beitrag Nr.: 30.931.273 von c-laus am 30.07.07 08:29:20http://abclocal.go.com/kgo/story?section=edell&id=5494317
      Avatar
      schrieb am 06.08.07 11:02:23
      Beitrag Nr. 41 ()
      Heute sollen die Quartalszahlen kommen von dieser wirklich mies performenden Aktie!

      Die Zahlen werden vermutlich gar nicht schlecht ausfallen. Ich vermute aktive Kursdrückerei mit einem bestimmten Zweck. Aber das werden wir sehen. Es bleibt spannend!
      Avatar
      schrieb am 08.08.07 08:27:29
      Beitrag Nr. 42 ()
      Antwort auf Beitrag Nr.: 31.047.927 von c-laus am 06.08.07 11:02:23Wieder verschoben worden. Definitiv am Donnerstag mit einem Konferenzcall.
      Ich werde berichten. Make your bet!
      Avatar
      schrieb am 09.08.07 15:10:46
      Beitrag Nr. 43 ()
      Antwort auf Beitrag Nr.: 31.073.520 von c-laus am 08.08.07 08:27:2908/09/07 Artes Medical Reports Second Quarter 2007 Financial Results


      SAN DIEGO--(BUSINESS WIRE)--Aug. 9, 2007--Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today reported recent company highlights and financial results for the second quarter ended June 30, 2007.

      Recent Company Highlights

      -- Total revenues were $4.2 million for the first six months of
      2007, which includes ArteFill(R) product sales of $3.5 million
      and technology license revenues of $732,000.

      -- Over 800 physicians have opened accounts with Artes Medical in
      order to offer ArteFill to their patients. Of these 800
      physicians, over 600 board certified dermatologists, plastic
      surgeons, and cosmetic surgeons have completed their ArteFill
      training and are currently listed on the "Find A Doctor"
      physician locator on the ArteFill.com website, providing
      consumers the opportunity to easily identify an
      ArteFill-trained physician in their area.

      -- Presentation of 5 year U.S. pivotal study results were
      presented by Steven R. Cohen, M.D., F.A.C.S., Clinical
      Professor, Division of Plastic Surgery, University of
      California, San Diego, School of Medicine and lead ArteFill
      clinical investigator, at the annual meeting of the American
      Society for Aesthetic Plastic Surgery (ASAPS) in April 2007 in
      New York City. Additionally at ASAPS, over 400 physicians
      observed a live demonstration showing the straightforward
      nature of ArteFill's injection technique.

      -- Greg J. Kricorian, M.D., Chief Medical Officer, joined the
      Artes Medical team, and will have responsibility for Clinical
      Development and Medical Affairs. He will also chair the Artes
      Medical Advisory Board, and enhance the Company's involvement
      in the medical community.

      -- Artes announced the creation of a new wholly-owned subsidiary
      formed in order to pursue the development and
      commercialization of new and innovative medical applications
      of Artes Medical's proprietary microsphere tissue bulking
      technology through collaborative agreements with third
      parties.
      "We are pleased with our physician training efforts, and we now have over 600 physicians on our 'Find a Doctor' website locator. We are now accelerating our marketing efforts to increase both consumer and physician awareness of ArteFill's differentiated formulation that provides a safe and long-lasting solution for wrinkle correction of smile lines," said Diane S. Goostree, President and Chief Executive Officer.

      Financial Results

      The Company reported total revenues of $2.8 million for the three months ended June 30, 2007, which included ArteFill product sales of $2.1 million and technology license revenues of $732,000. The Company reported a net loss of $6.7 million for the three months ended June 30, 2007, an increase of $0.5 million compared to three months ended June 30, 2006 of $6.2 million. Gross profit for the three months ended June 30, 2007 was $628,000, which included an obsolete inventory reserve provision of $475,000 related to expired product produced in 2006 in anticipation of an earlier FDA approval and product launch. Total operating expenses for the three months ended June 30, 2007 were $7.5 million, an increase of $1.1 million, over the three months ended June 30, 2006 operating expenses of $6.4 million. The increase in second quarter 2007 operating expenses compared to second quarter 2006 is primarily attributable to the transition of the Company from a development stage organization to a commercial operation required in order to manufacture and distribute our FDA-approved product ArteFill.

      Cash, cash equivalents and short-term investments were $31.0 million as of June 30,
      Avatar
      schrieb am 09.08.07 15:40:23
      Beitrag Nr. 44 ()
      Antwort auf Beitrag Nr.: 31.096.088 von c-laus am 09.08.07 15:10:46tja,

      die entscheidende information wohl mit absicht erst am ende - zahlen waren schlecht und reichen bei weitem nicht, um die kosten zu decken. die company steht zwar noch am anfang vom product launch, trotzdem sollte in q4, spätestens in q1 von 2008 gewinn gemacht werden:

      "The Company reported total revenues of $2.8 million for the three months ended June 30, 2007, which included ArteFill product sales of $2.1 million and technology license revenues of $732,000. The Company reported a net loss of $6.7 million for the three months ended June 30, 2007, an increase of $0.5 million compared to three months ended June 30, 2006 of $6.2 million. Gross profit for the three months ended June 30, 2007 was $628,000, which included an obsolete inventory reserve provision of $475,000 related to expired product produced in 2006 in anticipation of an earlier FDA approval and product launch."

      cu gulliver
      Avatar
      schrieb am 03.10.07 12:16:00
      Beitrag Nr. 45 ()
      Meiner Meinung nach ist das Management von Artes Medical unfähig, die Firma professionell zu leiten.
      Ähnliches habe ich bei einer anderen Firma, nämlich der deutschen Intershop AG (A0EPUH) erlebt. Seit Bestehen der Firma wurde niemals ein Gewinn erzielt. Schuld war einzig und allein das Management!
      Jetzt kommt der Hammer: Durch dieses W:O-Board haben sich viel Aktionäre (kleine wie größere) zusammengeschlossen und einen sogenannten Aktioärskreis Intershop gegründet. Auf der Hauptversammlung hatten wir fast 4.000.000 Stimmen zusammen und konnten so fast alle Punkte der Tagesordnung mit weit über 90 % beschließen.
      Seit April diesen Jahres sind der komplette AR und Vorstand ausgetauscht und seitdem befindet sich Interhop auf Erfolgskurs. Die Aktie hat sich bereits mehr als verdoppelt.

      DIESES VORGEHEN SOLLTEN WIR UNS AUCH FÜR ARTES MEDICAL ÜBERLEGEN!!!
      Ich kenne einige Investoren, die über einen beträchtlichen Bestand an Artes-Aktien verfügen. Wenn wir unsere Kräfte bündeln, können wir bestimmt auch hier eine Palastrevolution durchführen. Denn auch die großen Investoren werden ihr Geld bestimmt nicht abschreiben wollen. Und das darf niemals vergessen werden: Wir Aktionäre sind die Eigentümer und der CEO ist lediglich unser Angestellter.
      Bitte um Eure Meinungen, ob Ihr Euch vorstellen könnt, einen solchen weg zu beschreiten.

      C-laus aus Frankfurt
      Avatar
      schrieb am 03.10.07 13:42:39
      Beitrag Nr. 46 ()
      Antwort auf Beitrag Nr.: 31.829.152 von c-laus am 03.10.07 12:16:00Robert B. Sherman, Former AOL and Time Warner Division President, Joins Artes Medical's Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--Oct. 3, 2007--Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced that Robert B. Sherman, former President, Interactive Marketing, America Online, Inc. has joined Artes Medical's Board of Directors. Mr. Sherman is currently a member of the Pilot Group, LLC, a private equity firm located in New York. Prior to joining AOL as President, Interactive Marketing, Mr. Sherman was President of Time Warner Cable Advertising Sales. He also formerly served as Executive Vice President of NBC's owned and operated radio stations and Chief Executive Officer of the advertising agency Della Femina, Travisano, Sherman & Olken, whose clients have included USA Network and Fox Television.

      "With the initial physician-driven phase of ArteFill market launch now underway, we will be expanding our sales force and initiating our consumer driven marketing activities, and we look forward to working with Bob Sherman, who has more than 30 years of advertising sales and agency experience and expertise as a high profile media executive in the traditional and new media," said Christopher J. Reinhard, Executive Chairman of Artes Medical.

      "Bob Sherman's record of success in on-line advertising and expertise as a media executive will be a tremendous asset to Artes Medical as we accelerate our consumer awareness and direct-to-consumer marketing campaign. ArteFill is a highly differentiated first-in-class non-resorbable dermal filler that provides truly long-lasting results for the correction of facial wrinkles. We look forward to working with Bob as we build innovative consumer awareness programs and enhance ArteFill's brand awareness to consumers," noted Mr. Reinhard.
      Avatar
      schrieb am 14.11.07 20:31:55
      Beitrag Nr. 47 ()
      Antwort auf Beitrag Nr.: 31.830.055 von c-laus am 03.10.07 13:42:39total üble zahlen. entweder die kriegen in 3 quartalen den turnaround hin, was ich net glaube, oder sie gehen hops und die konkursmasse wird von ner seniorcompany aufgekauft :O

      hoffe nicht, dass hier noch einer engagiert ist. die einschätzung von meinem letzten posting bleibt beibehalten:

      Artes Medical Reports Third Quarter 2007 Financial Results; Announces New Initiatives to Increase Sales Force, Training of Physicians and Consumer Awareness
      Tuesday November 13, 4:35 pm ET


      SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq: ARTE - News), a medical technology company whose product ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of “smile line” wrinkles, today reported financial results for the three and nine months ended September 30, 2007.

      ADVERTISEMENT
      The Company also announced a number of significant strategic initiatives intended to significantly expand the Company’s sales force, the number of physicians trained on the use of ArteFill, and additional programs to increase awareness and demand from consumers.

      Revenues for the third quarter were $6.7 million, which included $1.2 million in ArteFill product sales and $5.5 million in revenue from BioForm Medical, Inc. in lieu of future royalty obligations. Revenues for the nine months ended September 30, 2007 totaled $10.9 million, which includes $4.7 million of ArteFill product sales and $6.2 million of license revenue.

      The Company reported a net loss of $3.7 million ($0.22 per share) for the three months ended September 30, 2007, compared to a net loss of $4.4 million for the comparable three months in 2006. The net loss for the nine months ended September 30, 2007 was $16.9 million ($1.03 per share) compared to a net loss of $18.6 million for the nine months ended September 30, 2006. The results for the three and nine months ended September 30, 2007 reflect the Company’s transition from development stage activities in 2006 to commercial operations in 2007.

      The Company believes that product sales in the third quarter were impacted by the seasonality of the aesthetics industry as many doctors and their patients take vacations during the summer months. Product sales also reflect the impact of the Company’s relatively small sales force which limited its initial physician-centric outreach during the quarter.

      New Marketing Initiatives

      The Company announced a series of strategic marketing initiatives to accelerate the growth and acceptance of ArteFill. These initiatives include immediate steps to expand the size of the sales force along with advertising, public relations and online initiatives to reach out directly to consumers:

      * Expansion of Sales Force: Plans are underway to increase the number of the Company’s sales representatives from the current 21 sales representatives to 30 sales representatives by the end of this year. With these 30 sales representatives, the Company expects to train 1,000 physicians by the end of 2007. Continued sales force expansion to 60 sales representatives by the second quarter of 2008 will enable the company to train over 1,800 physicians by the end of 2008.
      * Increased Training of Physicians: Over 1,100 physicians have opened accounts with Artes Medical in order to offer ArteFill to their patients. Over 800 board certified dermatologists, plastic surgeons, and cosmetic surgeons have completed their ArteFill training, surpassing the original target of 600 trained physicians by the end of 2007.
      * Accelerated Direct Marketing Initiatives: The Company’s direct marketing initiatives include online marketing such as a partnership with iVillage, the #1 women’s community website, which is viewed by more than 17 million visitors per month. In addition, the Company has placed focused regional print advertising in key publications within major metropolitan markets, including the New York Times: “T” Magazine, which is an insert that reaches 1.7 million readers.

      Other Developments

      * The reorder rate for ArteFill is increasing over time. The ArteFill reorder rate is highest among the physicians who have the longest experience with the product, and increases the longer a physician has used ArteFill in his or her medical practice. Of those physicians who were trained, and who placed their first order in the Company’s first month of launch, February 2007, 85% of these physicians have reordered. On the average, physicians are increasing their order sizes with each reorder, demonstrating an accelerating uptake of the product within their practices.
      * The Company’s 5-year safety and efficacy data is contained in an article which has been accepted and is expected to be published by the end of 2007 in the peer-reviewed publication, Journal of Dermatologic Surgery “Filler Issue”. ArteFill’s 5-year safety and efficacy data was also presented by key opinion leaders at The 21st World Congress of Dermatology held in Buenos Aires, Argentina; the 34th Annual Scientific Meeting of the American Society for Dermatologic Surgery (ASDS) in Chicago, IL; NYC Aging Face Conference in New York City; and The American Society of Plastic Surgeons (ASPS) "Plastic Surgery 2007" in Baltimore, Maryland.
      * Additional clinical studies are underway. Studies have begun to help both physicians and patients understand more about ArteFill, and to help support the patient’s decision to be treated with ArteFill. A 1,000-patient long-term study to generate additional safety and efficacy data began in August 2007. A head-to-head clinical comparison with temporary dermal fillers Radiesse and Restylane has been initiated by Stacy R. Smith, M.D., President, Therapeutics Clinical Research, Assistant Clinical Professor of Dermatology, University of California San Diego, Division of Dermatology. Artes Medical has provided an unrestricted clinical research grant to Dr. Smith. He will be assessing longevity of wrinkle correction, safety profiles, and patient preference over a 24-month period.
      * The Company’s Board of Directors has been further strengthened with the recent addition of Beverly Huss and Robert Sherman to the Board. Beverly Huss has over 20 years of experience in medical device research and development, and has experience both as an operating executive in the medical device industry and as a public company director. The second new Board member is Robert Sherman, who has more than 30 years of advertising sales and agency experience and expertise as a high profile media executive in the traditional and new media.

      “We intend to build upon ArteFill’s competitive advantage as the only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds,” said Diane S. Goostree, President and Chief Executive Officer. “Our larger sales force and growing consumer outreach will allow us to educate physicians and consumers about the significant differences and advantages of ArteFill compared to temporary fillers.”

      Financial Results

      The Company reported total revenues of $6.7 million for the three months ended September 30, 2007, which included ArteFill product sales of $1.2 million and $5.5 million in revenues from BioForm Medical, Inc., in lieu of future royalty obligations. For the nine months ended September 30, 2007, the Company reported total revenues of $10.9 million, which includes $4.7 million of ArteFill product sales and $6.2 million of license revenue.

      The Company reported a net loss of $3.7 million for the three months ended September 30, 2007; a decrease of $0.7 million compared to the three months ended September 30, 2006 of $4.4 million. Net loss for the nine months ended September 30, 2007 was $16.9 million, a decrease of $1.7 million over the nine months ended September 30, 2006 of $18.6 million. Gross profit for the three and nine months ended September 30, 2007 was $3.7 million and $4.1 million, respectively. Total operating expenses for the three months ended September 30, 2007 were $7.4 million, an increase of $2.8 million over the three months ended September 30, 2006 operating expenses of $4.6 million. Total operating expenses for the nine months ended September 30, 2007 were $21.5 million, an increase of $4.3 million over the nine months ended September 30, 2006 operating expenses of $17.2 million. The increase in operating expenses for both the three and nine months ended September 30, 2007 compared to the similar periods in 2006 was primarily due to the Company’s transition from development stage activities in 2006 to commercial operations in 2007.

      Cash, cash equivalents and short-term investments were $23.0 million as of September 30, 2007, which exclude the $5.5 million pre-payment from BioForm Medical, Inc. of future royalty obligations to the Company.

      Conference Call and Webcast Information

      Artes Medical will host a webcast and conference call today, November 13, 2007 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the financial results. The dial-in numbers are (866) 700-7477 for domestic callers, and (617) 213-8840 for international callers. The passcode for both domestic and international callers is 61763260. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.artesmedical.com. Participating in the call will be Diane S. Goostree, President and Chief Executive Officer, and Peter C. Wulff, Executive Vice President and Chief Financial Officer.

      After the live webcast, the call will remain available on Artes Medical's web site for at least 30 days following the presentation. In addition, a telephonic replay of the call will be available for 7 days. The replay dial-in numbers are (888) 286-8010 for domestic callers, and (617) 801-6888 for international callers. The passcode for both domestic and international callers is 81923092.
      Avatar
      schrieb am 30.11.07 14:59:56
      Beitrag Nr. 48 ()
      Antwort auf Beitrag Nr.: 32.429.634 von Gulliver am 14.11.07 20:31:55Ich gebe Dir Recht. Die Zahlen sind desaströs!

      Trotzdem habe ich letzte Woche bei 2,20 $ kräftig eingesammelt.
      Denn das Produkt ist hervorragend und ich habe gehört, dass es Adressen gibt, die eine Übernahme planen könnten.
      Das Problem ist derzeit das Management. Sollte dies kurzfristig ausgetauscht werden, gibt es einen Hype.
      Und eines ist klar: Gelingt es der Firma rechtzeitig den break-even zu schaffen, ist Arte ein Kandidat für einen Tenbugger vom heutigen Kurs!


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Artes Medical - Börsengang mit Top Aussichten